The first customer meeting is where a healthcare startup discovers whether its elegant software can survive contact with a hospital. Procurement wants proof. Clinicians want fewer clicks. Security wants a review. Finance wants a return. A founder who believed she was selling one product suddenly finds five constituencies sitting across the table. Wavemaker Three-Sixty Health has built its venture model around that crowded room.
The Pasadena firm, usually shortened to Wavemaker 360, invests primarily at seed stage in healthcare technology. Its portfolio ranges from personalized spinal implants and ambient medical scribes to remote monitoring, patient-controlled data, mental-health tools and software for clinical trials. The connecting idea is deliberately broader than a single technology. Care is shifting from hospitals into homes, devices and screens; payment is slowly shifting from volume toward value; and old workflows are colliding with AI, sensors and increasingly usable data.
Many funds see that same opening. Wavemaker 360’s more distinctive move was to recruit its own investors as part of the machinery. The firm says more than 300 limited partners sit behind its funds, with the majority coming from healthcare organizations or the industry’s executive and clinical ranks. A cap table that would normally be invisible to portfolio operations becomes a reference network: people who can challenge a reimbursement assumption, explain how a health system buys, assess a medical device or make a relevant introduction.
A consultancy learns to invest
Wavemaker 360 took shape in 2017 through Three-Sixty Advisory Group, a boutique healthcare consultancy, and Wavemaker, an established early-stage venture platform. The combination explains the firm’s split personality. It looks for venture-scale returns, but it talks about healthcare with an operator’s appetite for process: who pays, where a tool enters the workflow, which regulation applies and whether the promised savings accrue to the same institution asked to buy it.
John G. Nackel, the founder and general partner, had already spent decades in healthcare leadership and consulting, including at Ernst & Young and UnitedHealth Group’s Ingenix Consulting, now part of Optum. General partner Jay Goss brought a career of building and operating young companies. The current roster adds clinicians, former health-system executives, investors, an AI specialist and regulatory expertise. Venture partner Kwame Ulmer, for example, spent 12 years at the US Food and Drug Administration and has evaluated more than 1,000 medical technologies.
“We’re helping early-stage health technology companies get in those meeting rooms - with health systems and insurance companies - and sign those commercial contracts.”Maxim Owen, partner, speaking to BioscienceLA
That quote locates the actual product. Wavemaker 360 is not selling software or operating clinics. It raises money from limited partners, buys equity in young companies and seeks returns when those companies grow or exit. But a founder’s practical service experience is capital plus market navigation. The team offers diligence and operating judgment; the network can offer context and access. Fund III formalized part of that approach through a Portfolio Support Alliance, a curated group of experienced LPs assembled to assist with deal flow, diligence and commercial support.
Five ways to earn a place
The firm’s public thesis is summarized as a “Quintuple Aim.” It begins with two goals that every healthcare presentation claims - better outcomes and lower costs - then adds patient experience, clinician experience and new revenue for providers. The fifth is easily overlooked. A product can be medically useful and still struggle if the buyer cannot see a financial path. Wavemaker 360 explicitly looks for business models that help squeezed practices and clinics create revenue, alongside technologies that save money.
As a diligence device, the framework is useful because it forces a young company to name the beneficiary. DeepScribe’s ambient AI documentation can reduce clerical burden for clinicians. Carlsmed’s patient-specific spinal implants aim at surgical outcomes. Skin Analytics uses computer vision to extend skin-cancer assessment. Luna moves physical therapy into the home while working through insurance. Selfii turns patient-consented clinical records into a medical knowledge graph. Different products, different buyers, but each must show where value lands.
The mandate is wide: health-tech, digital health, medical devices, telehealth, AI, pharma-tech, marketplaces and science companies. Drug discovery is the clear exclusion. Geography is similarly practical. The United States remains central because healthcare investing demands local knowledge of payment and regulation. The firm also considers Canada, Western Europe and parts of Asia when a company has a near-term US expansion plan.
The check is only the beginning
Fund I raised a reported $16.9 million in 2018. Fund II closed at $64 million in June 2022, roughly quadrupling the first vehicle, with a plan to invest in 40 to 50 companies. By then Wavemaker 360 had already invested in 45 businesses across the United States, Canada, Europe and Singapore. One early Fund II result came in October 2021, when Carbon Health acquired remote patient monitoring company Alertive Healthcare.
Growth of the platform
Fund sizes are committed capital, not company revenue. Fund III size has not been publicly stated on the firm’s main website.Fund III is identified as a 2025 vintage, and public profiles put total assets under management near $200 million. The firm’s own site currently reports 74 companies across three funds. Those numbers place it between a small specialist seed shop and the larger multistage healthcare funds. It has enough breadth to see patterns across devices, care delivery and software, while its public identity remains fixed on early-stage healthcare.
Its alternatives are not only other specialist investors such as 7wireVentures, Define Ventures, Flare Capital or HealthQuest. A founder can also take money from a generalist seed fund, a hospital system’s venture arm, a device maker or a strategic corporate investor. Wavemaker 360’s pitch is that specialization improves the quality of the first questions and the usefulness of the next introductions. That claim ultimately depends on execution: a large network matters only when someone chooses the right connection and follows through.
A bridge, not a sightseeing tour
The 2023 partnership with GMA Ventures shows how the model can travel. The two organizations agreed to identify promising Philippine health-tech entrepreneurs and help them expand to the United States, while supporting US portfolio companies entering Southeast Asia. GMA later disclosed a $1 million commitment to Wavemaker Three-Sixty Health II A, L.P. It is a tidy example of an LP relationship becoming something more operational: capital, local knowledge and a route into another healthcare market.
The challenge is that healthcare does not globalize like consumer software. Payment systems, clinical pathways, licensing and data rules change at each border. A two-way bridge needs more than a warm introduction. It needs founders willing to adapt products and economics to a new system. Wavemaker 360’s own FAQ reflects that caution, limiting many international bets to companies with concrete plans for the US.
What founders can borrow
There is a lesson here even for companies that never pitch the firm. Build the investor group as if it were part of customer development. An impressive name is less useful than a person who understands the buyer, can identify a fatal workflow flaw and will answer when the founder calls. In healthcare, where adoption depends on trust and institutional memory, that difference compounds.
Wavemaker 360’s “Founder’s FAQ” is another small, stealable idea. It explains sector fit, stage, geography, fund size and the LP network before the meeting. Fundraising is opaque enough; publishing the basic rules allows both sides to disqualify a mismatch early. That leaves more time for the questions that matter: Who changes behavior? Who captures the savings? What evidence does the buyer require? What happens when the pilot meets the real clinical day?
The firm’s portfolio news in 2026 offers signs of companies moving beyond that first room. Iterative Health raised a $77 million Series C. Gradient Health expanded its medical-data platform beyond imaging. Tombot raised $7 million to scale robotic companion products. These are portfolio-company events, not proof of a fund-level return. They do show the variety of paths a seed investor must be prepared to understand.
Wavemaker 360 fits into the market as a specialist connector: smaller and earlier than the giant healthcare funds, more domain-bound than a generalist, and unusually explicit about turning healthcare investors into working infrastructure. The cleverness is not mysterious. Healthcare is a relationship business wrapped around regulated science and complicated economics. The fund simply designed its network to admit that from day one.